Literature DB >> 25586652

Predictors of AA amyloidosis in familial Mediterranean fever.

Nikolay A Mukhin1, Lidiya V Kozlovskaya, Marina V Bogdanova, Vilen V Rameev, Sergey V Moiseev, Armine Kh Simonyan.   

Abstract

The aim of the study was to evaluate the clinical and genetic predictors of AA amyloidosis in patients with familial Mediterranean fever (FMF). We retrospectively studied 170 Armenian patients who were admitted to the two tertiary centers in 2003-2014. The diagnosis of amyloidosis that was suspected clinically (new proteinuria or nephrotic syndrome) was confirmed histologically. Screening for MEFV gene mutations was performed in 70 patients. The most common genotype was M694V/M694V (in 36 % of patients). Biopsy-proven AA amyloidosis was found in 102 (60 %) of 170 patients. AA amyloidosis was diagnosed in 17 (68 %) of 25 patients with homozygous M694V mutation, 17 (53 %) of 32 patients with heterozygous M694V allele and 4 (31 %) of 13 patients with other MEFV gene mutations. The M694V homozygosity and heterozygosity were associated with increased risk of AA amyloidosis, but this association did not reach statistical significance (odds ratio 2.43; 95 % CI 0.87-6.76, and 3.33; 0.91-12.1, respectively). Male gender, early onset of disease, severity of FMF, frequent attacks, peritonitis, pleuritis and erysipelas-like erythema also did not predict AA amyloidosis development. Recurrent arthritis was the only clinical finding that was significantly associated with AA amyloidosis (odds ratio 2.28; 95 % CI 1.17-4.42). Involvement of the joint synovial membrane, that is capable of active serum amyloid A production, is the main predictor of renal amyloidosis in FMF.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25586652     DOI: 10.1007/s00296-014-3205-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  20 in total

1.  The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever.

Authors:  Ruth Gershoni-Baruch; Riva Brik; Nurit Zacks; Maruan Shinawi; Merav Lidar; Avi Livneh
Journal:  Arthritis Rheum       Date:  2003-04

2.  MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications.

Authors:  C Cazeneuve; T Sarkisian; C Pêcheux; M Dervichian; B Nédelec; P Reinert; A Ayvazyan; J C Kouyoumdjian; H Ajrapetyan; M Delpech; M Goossens; C Dodé; G Grateau; S Amselem
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

3.  [Current methods of systemic amyloidosis diagnosis and monitoring of its course].

Authors:  V V Rameev; L V Kozlovskaia; E A Malinina; A G Serova; I N Kogarko; B S Kogarko; N V Liubimova
Journal:  Ter Arkh       Date:  2011       Impact factor: 0.467

4.  Genotype-phenotype assessment of common genotypes among patients with familial Mediterranean fever.

Authors:  Y Shinar; A Livneh; P Langevitz; N Zaks; I Aksentijevich; D E Koziol; D L Kastner; M Pras; E Pras
Journal:  J Rheumatol       Date:  2000-07       Impact factor: 4.666

5.  Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium.

Authors: 
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

6.  Criteria for the diagnosis of familial Mediterranean fever.

Authors:  A Livneh; P Langevitz; D Zemer; N Zaks; S Kees; T Lidar; A Migdal; S Padeh; M Pras
Journal:  Arthritis Rheum       Date:  1997-10

Review 7.  Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health.

Authors:  J Samuels; I Aksentijevich; Y Torosyan; M Centola; Z Deng; R Sood; D L Kastner
Journal:  Medicine (Baltimore)       Date:  1998-07       Impact factor: 1.889

8.  Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study.

Authors:  Timucin Kasifoglu; Sule Yasar Bilge; Ismail Sari; Dilek Solmaz; Soner Senel; Hakan Emmungil; Levent Kilic; Sibel Yilmaz Oner; Fatih Yildiz; Sedat Yilmaz; Duygu Ersozlu Bakirli; Muge Aydin Tufan; Sema Yilmaz; Veli Yazisiz; Yavuz Pehlivan; Cemal Bes; Gozde Yildirim Cetin; Sukran Erten; Emel Gonullu; Tuncer Temel; Fezan Sahin; Servet Akar; Kenan Aksu; Umut Kalyoncu; Haner Direskeneli; Eren Erken; Bunyamin Kisacik; Mehmet Sayarlioglu; Cengiz Korkmaz
Journal:  Rheumatology (Oxford)       Date:  2013-12-24       Impact factor: 7.580

9.  Analysis of the three most common MEFV mutations in 412 patients with familial Mediterranean fever.

Authors:  Nurit Zaks; Yael Shinar; Shai Padeh; Merav Lidar; Adam Mor; Irena Tokov; Mordechai Pras; Pnina Langevitz; Elon Pras; Avi Livneh
Journal:  Isr Med Assoc J       Date:  2003-08       Impact factor: 0.892

10.  Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean fever homozygous for the M694V-MEFV mutation.

Authors:  Ruth Gershoni-Baruch; Riva Brik; Merav Lidar; Marwan Shinawi; Avi Livneh
Journal:  J Rheumatol       Date:  2003-02       Impact factor: 4.666

View more
  5 in total

1.  The Relationship Among the Level of Serum Amyloid A, High-Density Lipoprotein and Microalbuminuria in Patients With Familial Mediterranean Fever.

Authors:  Ali Ugur Uslu; Bahattin Aydin; Ibrahim Serhat Icagasıoğlu; Sevket Balta; Köksal Deveci; Filiz Alkan; Gürsel Yıldız; Ali Sahin
Journal:  J Clin Lab Anal       Date:  2016-04-19       Impact factor: 2.352

2.  Shear wave elastography evaluation of liver, pancreas, spleen and kidneys in patients with familial mediterranean fever and amyloidosis.

Authors:  Zuhal Bayramoglu; Zeynep Nur Akyol Sari; Oya Koker; Ibrahim Adaletli; Rukiye Eker Omeroglu
Journal:  Br J Radiol       Date:  2021-09-14       Impact factor: 3.039

3.  Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever.

Authors:  Yusuf Karabulut; Halise Hande Gezer; Nuran Öz; İrfan Esen; Mehmet Tuncay Duruöz
Journal:  Rheumatol Int       Date:  2022-09-01       Impact factor: 3.580

Review 4.  The NLRP3 and Pyrin Inflammasomes: Implications in the Pathophysiology of Autoinflammatory Diseases.

Authors:  Carlos de Torre-Minguela; Pablo Mesa Del Castillo; Pablo Pelegrín
Journal:  Front Immunol       Date:  2017-01-27       Impact factor: 7.561

Review 5.  [What is confirmed in the treatment of autoinflammatory fever diseases?]

Authors:  Anne Pankow; Eugen Feist; Ulrich Baumann; Martin Kirschstein; Gerd-Rüdiger Burmester; Annette Doris Wagner
Journal:  Internist (Berl)       Date:  2021-12-08       Impact factor: 0.743

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.